ORL; journal for oto-rhino-laryngology and its related specialties · 2011
Evaluation of long-term clarithromycin treatment in adult Chinese Patients with chronic rhinosinusitis without nasal polyps.
Сравнительное исследованиеСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Luo Qing, Chen Fenghong, Liu Wenlong, Li Zuwang, Xu Rui, Fan Yunping, Chen Rong, Xu Yu, Liu Zheng, Xu Geng, Fu Qingling, Zuo Kejun, Shi Jianbo, Li Huabin, Nasal Health Group, China (NHGC)
Аннотация
OBJECTIVE: To evaluate the efficacy of long-term clarithromycin (CAM) treatment in adult Chinese patients suffering from chronic rhinosinusitis without nasal polyps (CRSnNP).
METHODS: Thirty-three CRSnNP patients were enrolled and subjected to CAM treatment for 12 weeks (250 mg daily). The total nasal symptom scores (TNSS), nasal resistance and inflammatory mediators including interleukin (IL)-8 and myeloperoxidase (MPO) were evaluated at weeks 0 and 12. Quality of life (QoL) was assessed in all patients by using the Sinonasal Outcome Test 20 and Short Form 36 questionnaires.
RESULTS: CAM treatment significantly improved TNSS, nasal resistance and QoL, and it inhibited IL-8 and MPO production in CRSnNP patients (p < 0.05). CAM treatment was more effective for IL-8(high) CRSnNP patients than for IL-8(low) CRSnNP patients (p < 0.05).
CONCLUSION: Long-term, low-dose CAM treatment is effective and safe for the treatment of CRSnNP in Chinese patients.
METHODS: Thirty-three CRSnNP patients were enrolled and subjected to CAM treatment for 12 weeks (250 mg daily). The total nasal symptom scores (TNSS), nasal resistance and inflammatory mediators including interleukin (IL)-8 and myeloperoxidase (MPO) were evaluated at weeks 0 and 12. Quality of life (QoL) was assessed in all patients by using the Sinonasal Outcome Test 20 and Short Form 36 questionnaires.
RESULTS: CAM treatment significantly improved TNSS, nasal resistance and QoL, and it inhibited IL-8 and MPO production in CRSnNP patients (p < 0.05). CAM treatment was more effective for IL-8(high) CRSnNP patients than for IL-8(low) CRSnNP patients (p < 0.05).
CONCLUSION: Long-term, low-dose CAM treatment is effective and safe for the treatment of CRSnNP in Chinese patients.